Vinva Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vinva Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40,321	Closed	-$556K	–	478
2026 Q1	$556K	Buy	40,321 +21,588	+115%	+$168K	0.01%	378
2025 Q4	$214K	Sell	18,733 -34,328	-65%	-$248K	﹤0.01%	392
2025 Q3	$609K	Sell	53,061 -267	-0.5%	-$2.22K	0.01%	362
2025 Q2	$765K	Buy	+53,328	New	+$497K	0.02%	325

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Vinva Investment Management's BCRX Position: Q2 2026 in Review

Vinva Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 40,321 shares — an estimated $556K sold.

Vinva Investment Management first reported a position in BCRX in Q2 2025 and held it in 4 quarters. The position peaked at $765K in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Vinva Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Vinva Investment Management sold 40,321 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $556K.
Vinva Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Vinva Investment Management's BioCryst Pharmaceuticals position peaked at $765K in Q2 2025.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Vinva Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.